1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA) (NIH). This program aims to enhance the training of a workforce skilled in biomedical, behavioral, and clinical research, particularly regarding substance use disorders.
It supports educational activities that prepare clinicians and clinical researchers, with a focus on institutional career development support.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Clinician-scientist training programs in addiction and substance use disorders in North Carolina can apply for institutional career development support. Eligible institutions provide intensive, supervised research training that advances substance use and substance use disorder research toward independent clinical research careers. This initiative does not fund non-research-related clinical training. Confirm the full requirements in the official notice before applying.
The current listing shows up to $750,000 (for institutional career development support). Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) is funded by National Institute on Drug Abuse (NIDA) (NIH). Verify program details on the funder's official page before applying.
This opportunity targets applicants in North Carolina. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleNICHD forecast RFA-HD-28-005 (CAPSTONE), RFA-HD-28-006 (Learning Disabilities Research Centers), and RFA-HD-28-001 (Discovery Gateway) on October 20, 2026. All three are due around October 1, 2027. Here is what the incumbents hold and how challengers should prepare.
Read articleNIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read article